Arrakis Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 113

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 15

Arrakis Therapeutics General Information

Description

Developer of a drug discovery platform designed to find new points of therapeutic intervention. The company's platform integrates RNA bioinformatics, chemical biology tools, chemical and biological assays, and RNA-directed medicinal chemistry, enabling physicians to treat a range of diseases including neurology, oncology, and rare genetic diseases.

Contact Information

Website
www.arrakistx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
  • 828 Winter Street
  • Waltham, MA 02451
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Arrakis Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC 01-Jan-2020 00000 Completed Generating Revenue
3. Early Stage VC (Series B) 10-Apr-2019 0000 00000 00000 Completed Generating Revenue
2. Early Stage VC (Series A) 02-Mar-2017 $38.5M $40.5M 0000 Completed Generating Revenue
1. Seed Round 01-Jan-2015 $2M $2M Completed Startup
To view Arrakis Therapeutics’s complete valuation and funding history, request access »

Arrakis Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B 00,000,000 00.000000 00.00 00.00 00.00 00.00 00.000
Series A 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
To view Arrakis Therapeutics’s complete cap table history, request access »

Arrakis Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a drug discovery platform designed to find new points of therapeutic intervention. The company's platform i
Drug Discovery
Waltham, MA
113 As of 2023
00000
0000000000 0 00000

000000

consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillu
0000000000000
Richmond, CA
000000000 -

000000

dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla par
0000 000000000
South San Francisco, CA
00 As of 0000
00000
0.000 0000-00-00
000000&0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Arrakis Therapeutics Competitors (117)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ProMab Biotechnologies Corporate Backed or Acquired Richmond, CA 000000000 -
000000 00000000000 Formerly PE-Backed South San Francisco, CA 00 00000 000000&0 00000
0000000 0000000000 Formerly VC-backed Lexington, MA 000 00000 000000&0 00000
000000000 Venture Capital-Backed San Diego, CA 00 00000 0000000000 0 00000
000000 0000 000000 Corporation New York, NY 00 00.00 000000 - 000 00.00
You’re viewing 5 of 117 competitors. Get the full list »

Arrakis Therapeutics Patents

  • 19

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 000

    Granted

  • 1

    Pending

  • 000

    Expiring in next 12 mo

Arrakis Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2018374389-A1 Nucleic acid-binding photoprobes and uses thereof Pending 30-Nov-2017 0000000000
CA-3078540-A1 Nucleic acid-binding photoprobes and uses thereof Pending 30-Nov-2017 0000000000
EP-3717009-A1 Nucleic acid-binding photoprobes and uses thereof Pending 30-Nov-2017 0000000000
EP-3717009-A4 Nucleic acid-binding photoprobes and uses thereof Pending 30-Nov-2017 0000000000 0
US-20190270723-A1 Nucleic acid-binding photoprobes and uses thereof Pending 30-Nov-2017 C07D401/14
To view Arrakis Therapeutics’s complete patent history, request access »

Arrakis Therapeutics Executive Team (14)

Name Title Board Seat Contact Info
Jacques Dumas Ph.D Chief Scientific Officer
William Tang Director of Finance
Jennifer Petter Ph.D Co-Founder & Chief Innovation Officer
James Mutamba Ph.D Chief Business Officer
Erik Spek Ph.D Senior Vice President, Legal
You’re viewing 5 of 14 executive team members. Get the full list »

Arrakis Therapeutics Board Members (15)

Name Representing Role Since
Alan Walts Ph.D Arrakis Therapeutics Board Observer 000 0000
Christopher O'Donnell Ph.D Pfizer Ventures Board Member 000 0000
Colleen Cuffaro Ph.D Canaan Partners Board Member 000 0000
Elaine Jones Ph.D Pfizer Ventures Board Observer & Board Member 000 0000
Jakob Loven Ph.D Nextech Invest Board Member 000 0000
You’re viewing 5 of 15 board members. Get the full list »

Arrakis Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Arrakis Therapeutics Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Alexandria Venture Investments Corporate Venture Capital Minority 000 0000 000000 0
GV Corporate Venture Capital Minority 000 0000 000000 0
HBM Healthcare Investments Venture Capital Minority 000 0000 000000 0
HBM Partners Venture Capital Minority 000 0000 000000 0
Nextech Invest Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 15 investors. Get the full list »

Ready to get started?

Request a free trial